Product Program year 2021 Source: CMS Open Payments

Nocdurna

Drug Urology

NDC 55566-5050-1

Open in the dashboard

General payments

$424,855

3,723 payments

Research payments

$3,380,901

528 payments

Through program year 2021, $424,855 in general payments and $3,380,901 in research payments were reported against Nocdurna (Urology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

6 rows
Year Kind Amount Payments
2021 General $19,865 4
2021 Research $2,499 1
2020 General $94,343 226
2020 Research $785,863 144
2019 General $310,647 3,493
2019 Research $2,592,540 383

Breakdown

Who paid General payments · program years 2019–2021
  1. Ferring Pharmaceuticals Inc. $401,335 3,664 payments
  2. Ferring Pharmaceuticals AS $23,012 48 payments
  3. Ferring International Pharmascience Center US $439 10 payments
  4. Ferring International Center SA $69 1 payment
Top recipients General payments · program year 2021
  1. Matt Rosenberg Family Medicine · Jackson, MI $7,196 36% · 1 payment
  2. Jeffrey Weiss Urology · Brooklyn, NY $6,400 32% · 1 payment
  3. Bilal Chughtai Urology · New York, NY $6,200 31% · 1 payment
  4. Fady Sharara Reproductive Endocrinology · Reston, VA $69 <1% · 1 payment

Each share is of general payments naming this product in 2021.

Specialties paid General payments · program year 2021
  1. Urology $12,600 63% · 2 practitioners
  2. Family Medicine $7,196 36% · 1 practitioner
  3. Reproductive Endocrinology Obstetrics & Gynecology $69 <1% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2021
  1. New York $12,600 63% · 2 recipients
  2. Michigan $7,196 36% · 1 recipient
  3. Virginia $69 <1% · 1 recipient

Each share is of general payments naming this product in 2021 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

24

Prescriptions dispensed, refills included

Drug cost

$11,889

Paid at the pharmacy, in all

Prescribers

2

With 11 or more claims of it

Medicare Part D drugs matched to NOCDURNA, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Nocdurna Desmopressin Acetate Same name 2 24 $11,889

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

2 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Irvin Hirsch Urology PA 13 $6,563 None on record
Rupa Kitchens Urology AL 11 $5,326 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

3,723 general · 528 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record